Cohort Studyhigh evidence
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances·July 1, 2026·PMID 42489387
Why it mattersHead-to-head cardiovascular outcome data between these two widely used incretin-based agents are limited, and clinicians need evidence to guide agent selection, particularly as use expands beyond diabetes into obesity management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled